Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mannkind Corp. (MNKD)
NASDAQ:MNKD
Holding MNKD?
Track your performance easily
MNKD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.17 - $7.63
Previous CloseN/A
Volume434.88K
Average Volume (3M)2.68M
Market Cap
$1.66B
Enterprise Value$1.89B
Total Cash (Recent Filing)$22.89M
Total Debt (Recent Filing)$77.16M
Price to Earnings (P/E)86.3
Beta0.89
Next Earnings
Mar 04, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding275,777,680
10 Day Avg. Volume1,882,742
30 Day Avg. Volume2,677,719
Standard Deviation0.18
R-Squared0.14
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.26
Price to Cash Flow (P/CF)44.90
P/FCF Ratio52.90
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue7.26
Enterprise Value/Gross Profit13.85
Enterprise Value/Ebitda35.25
Forecast
1Y Price Target
$10.00Price Target Upside66.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
MannKind News
PremiumCompany Announcements
MannKind Announces Upcoming Retirement of Lauren Sabella
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsMNKD-201 program for IPF could bypass severe GI side effects by delivering the drug directly to the lungs, potentially increasing treatment efficacy.
Financial PerformanceThe company is now durably cash flow positive and mostly de-levered, which is seen as positive for the fundamental outlook.
Pipeline DevelopmentThe MNKD-101 program targets NTM lung disease and offers potential opportunities significantly larger than the current business.
Bears Say
Clinical Development ChallengesObservations of lung toxicity, including cough and FEV-1 drop, during the Phase 1 study of MNKD-201 raise concerns about the drug's safety profile.
Financial RisksPotential financial needs for raising capital may pose a risk to the company's stability and growth prospects.
Product ImpactAfrezza represents a small part of the company's valuation, suggesting it might not significantly influence the stock's performance.
---
Ownership Overview
3.02% Insiders
12.07% Mutual Funds
0.95% Other Institutional Investors
69.71% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MNKD FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was $3.17 and its highest was $7.63 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is $1.66B.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is Mar 04, 2025 which is in 45 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Nov 07, 2024. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.01.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is 0.03.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 275,777,680 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of $0.04 in its last earnings report, beating expectations of $0.03. Following the earnings report the stock price went down -0.677%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Among the largest hedge funds holding Mannkind Corp.’s share is Bruce & Co., Inc.. It holds Mannkind Corp.’s shares valued at 1M.
---
MannKind Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (66.39% Upside)
$10.00 (66.39% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 87%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 91.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.48%
12-Months-Change
Fundamentals
Return on Equity
-10.27%
Trailing 12-Months
Asset Growth
44.91%
Trailing 12-Months
Company Description
Mannkind Corp.
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
---
MNKD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive overall sentiment with strong revenue growth and successful collaborations driving optimism. However, challenges like Afrezza headwinds and market difficulties in NTM lung disease were noted.Read More>---
MNKD Stock 12 Month Forecast
Average Price Target
$10.00
▲(66.39% Upside)
Technical Analysis
Soligenix
―
SCYNEXIS
―
Armata Pharmaceuticals
―
Rigel
―
Sarepta Therapeutics
―
Kala Pharmaceuticals
―
Best Analysts Covering MNKD
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+42.20%
reiterated a buy rating 2 months ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +42.20% per trade.
---